Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis

doi:10.1016/0014-2999(88)90284-1

European Journal of Pharmacology

Volume 156, Issue 3, 8 November 1988, Pages 385-393

https://doi.org/10.1016/0014-2999(88)90284-1 Get rights and content

Abstract

The effect on dopamine (DA) release of D-1 and D-2 receptor agonists and antagonists applied locally in the caudate through a trans-striatal dialysis probe was studied in freely moving rats. D-2 agonists (LY 171555 and BHT 920) reduced DA release in a concentration-dependent manner. The same local application of haloperidol abolished the effect of 10 μM LY 171555 and BHT 920. A specific D-1 agonist, the catechol benzazepine SKF 38393, reduced DA release and this effect was not modified by systemic or local administration of the D-1 antagonist, SCH 23390, nor by the D-2 antagonist, haloperidol. In contrast, the non-catechol D-1 agonist, CY 208243, failed to modify DA release. Local application of the D-1 antagonist, SCH 23390, or of the D-2 antagonist, (−)-sulpiride, stimulated DA release in a concentration-dependent manner. The D-1 agonist, CY 20843, reversed the stimulatory effect of SCH 23390 but not that of (−)-sulpiride. It is concluded that D-1 and D-2 receptors located in the caudate control DA release separately in this area.

References (37)

N.E. Andén et al.
Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons
European J. Pharmacol.
(1971)
S. Arbilla et al.
Stereoselectivity of presynaptic autoreceptors modulating dopamine release
European J. Pharmacol.
(1981)
M.-F. Chesselet
Presynaptic regulation of neurotransmitter release in the brain
Neuroscience
(1984)
G. Di Chiara et al.
Haloperidol increases and apomorphine decreases striatal dopamine metabolism after destruction of striatal dopamine-sensitive adenylate-cyclase by kainic acid
Brain Res.
(1977)
D. Hinzen et al.
The dopamine autoreceptor agonist BHT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment
European J. Pharmacol.
(1986)
J. Hyttel
SCH 23390: the first selective dopamine D-1 antagonist
European J. Pharmacol.
(1983)
A. Imperato et al.
The D-1 antagonist SCH 23390 stimulates while D-1 agonist SKF 38393 fails to affect dopamine release in the dorsal caudate of freely moving rats
European J. Pharmacol.
(1987)
Y. Kondo et al.
Diminished responses of nigral dopaminergic neurons to haloperidol and morphine following lesions in the striatum
Brain Res.
(1980)
G.P. Mereu et al.
(−)-Sulpiride activates the firing rate and tyrosine hydroxylase activity of dopaminergic neurons in unanaesthetized rats
Brain Res.
(1983)
M. Morelli et al.
6-Hydroxydopamine lesions reduce specific [³H]sulpiride binding in the rat substantia nigra: direct evidence for the existence of nigral D-2 autoreceptors
European J. Pharmacol.
(1987)

P.E. Setler et al.

The central effects of a novel dopamine agonist

European J. Pharmacol.

(1978)

J.C. Stoof et al.

Two dopamine receptors: biochemistry, physiology and pharmacology

Life Sci.

(1984)

T. Zetterström et al.

Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis

European J. Pharmacol.

(1984)

G.K. Aghajanian et al.

Dopamine's autoreceptors: Pharmacological characterization by microiontophoretic single cell recording studies

Naunyn-Schmiedeb. Arch. Pharmacol.

(1977)

N.E. Andén

Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs

J. Pharmacol.

(1972)

N.E. Andén et al.

Selective stimulation of dopamine and noradrenaline autoreceptors by BHT 933, respectively

Naunyn-Schmiedeb. Arch. Pharmacol.

(1982)

H. Benveniste et al.

Regional cerebral glucose phosphorylation and blood flow after insertion of a microdialysis fiber through the dorsal hippocampus in the rat

J. Neurochem.

(1987)

B.A. Bunney et al.

Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity

J. Pharmacol. Exp. Ther.

(1973)

Cited by (126)

Immunolocalization of kappa opioid receptors in the axon initial segment of a group of embryonic mesencephalic dopamine neurons
2022, IBRO Neuroscience Reports
Citation Excerpt :
In the NAc, D2R are pre-synaptically localized on axon terminals and post-synaptically on dendrites of MSN GABA neurons (Pickel et al., 2006). Activation of D2R within the NAc decreases dopamine extracellular levels (Imperato and Di Chiara, 1988). Likewise, KORs are abundant in the mesolimbic system (Mansour et al., 1996) and negatively control dopamine neurotransmission.
The dopamine mesolimbic system is a major circuit involved in controlling goal-directed behaviors. Dopamine D2 receptors (D2R) and kappa opioid receptors (KOR) are abundant Gi protein-coupled receptors in the mesolimbic system. D2R and KOR share several functions in dopamine mesencephalic neurons, such as regulation of dopamine release and uptake, and firing of dopamine neurons. In addition, KOR and D2R modulate each other functioning. This evidence indicates that both receptors functionally interact, however, their colocalization in the mesostriatal system has not been addressed. Immunofluorescent assays were performed in cultured dopamine neurons and adult mice’s brain tissue to answer this question. We observed that KOR and D2R are present in similar density in dendrites and soma of cultured dopamine neurons, but in a segregated manner. Interestingly, KOR immunolabelling was observed in the first part of the axon, colocalizing with Ankyrin in 20% of cultured dopamine neurons, indicative that KOR is present in the axon initial segment (AIS) of a group of dopaminergic neurons. In the adult brain, KOR and D2R are also segregated in striatal tissue. While the KOR label is in fiber tracts such as the striatal streaks, corpus callosum, and anterior commissure, D2R is located mainly within the striatum and nucleus accumbens, surrounding fiber tracts. D2R is also localized in some fibers that are mostly different from those positives for KOR. In conclusion, KOR and D2R are present in the soma and dendrites of mesencephalic dopaminergic neurons, but KOR is also found in the AIS of a subpopulation of these neurons.
Behavioral sensitization to ethanol: Neural basis and factors that influence its acquisition and expression
2016, Brain Research Bulletin
Ethanol-induced behavioral sensitization (EBS) was first described in 1980, approximately 10 years after the phenomenon was described for psychostimulants. Ethanol acts on γ-aminobutyric acid (GABA) and glutamate receptors as an allosteric agonist and antagonist, respectively, but it also affects many other molecular targets. The multiplicity of factors involved in the behavioral and neurochemical effects of ethanol and the ensuing complexity may explain much of the apparent disparate results, found across different labs, regarding ethanol-induced behavioral sensitization. Although the mesocorticolimbic dopamine system plays an important role in EBS, we provide evidence of the involvement of other neurotransmitter systems, mainly the glutamatergic, GABAergic, and opioidergic systems. This review also analyses the neural underpinnings (e.g., induction of cellular transcription factors such as cyclic adenosine monophosphate response element binding protein and growth factors, such as the brain-derived neurotrophic factor) and other factors that influence the phenomenon, including age, sex, dose, and protocols of drug administration. One of the reasons that make EBS an attractive phenomenon is the assumption, firmly based on empirical evidence, that EBS and addiction-related processes have common molecular and neural basis. Therefore, EBS has been used as a model of addiction processes. We discuss the association between different measures of ethanol-induced reward and EBS. Parallels between the pharmacological basis of EBS and acute motor effects of ethanol are also discussed.
Effects of dopamine D<inf>1</inf> receptor activation and blockade on dopamine and noradrenaline levels in the rat brain
2016, Neuroscience Letters
The noradrenergic and dopaminergic systems are associated with the motor system and have anatomical and functional connections that have not yet been studied. The present study aimed to examine the specific role of D₁ receptors (D₁Rs) on noradrenergic and dopaminergic responses in the rat brain. Male Wistar rats were assigned to eight groups to receive systemic injection of a D₁R agonist (SKF-38393) at 0, 1, 5 or 10 mg/kg or injection of a D₁R antagonist (SCH-23390) at 0, 0.25, 0.5 or 1 mg/kg. Dopamine (DA) and noradrenaline (NA) levels were measured using high-performance liquid chromatography. Injection of SKF-38393 alone at 1, 5 and 10 mg/kg did not alter DA levels in the midbrain, cerebral cortex or pons, while it significantly increased these levels in the striatum (at 1 and 10 mg/kg), hippocampus (at 1 mg/kg) and cerebellum (at 1 and 5 mg/kg). Administration of SKF-38393 at 1, 5, and 10 mg/kg decreased the NA levels in the midbrain, pons, hippocampus (except at 1 mg/kg) and cortex (except at 5 mg/kg), whereas the opposite effect was observed in the striatum. SCH-23390 decreased the DA levels in the cortex (at 0.25 and 0.5 mg/kg) and pons (at 0.5 mg/kg). In contrast, 0.25, 0.5 and 1 mg/kg SCH-23390 increased the DA levels in the cerebellum, whereas no differences from the control levels were observed for the DA levels in the striatum, midbrain and hippocampus. SCH-23390 at 0.5 and 1 mg/kg increased the NA levels in the striatum. In contrast, the midbrain, hippocampus, cortex, pons and cerebellum did not exhibit altered NA levels. Our results demonstrate that the activation of D₁Rs modulates the response of the noradrenergic system in nearly all of the investigated brain structures; thus, the blockade of D₁Rs attenuates the effects induced by D₁R activation.
Regulation of Extracellular Dopamine: Release and Uptake
2016, Handbook of Behavioral Neuroscience
Dopamine (DA) transmission is governed by processes that regulate release from axonal boutons in the forebrain and the somatodendritic compartment in midbrain, and by clearance by the DA transporter, diffusion, and extracellular metabolism. We review how axonal DA release is regulated by neuronal activity and by autoreceptors and heteroreceptors, and address how quantal release events are regulated in size and frequency. In brain regions densely innervated by DA axons, DA clearance is due predominantly to uptake by the DA transporter, whereas in cortex, midbrain, and other regions with relatively sparse DA inputs, the noradrenaline transporter and diffusion are involved. We discuss the role of DA uptake in restricting the sphere of influence of DA and in temporal accumulation of extracellular DA levels upon successive action potentials. The tonic discharge activity of DA neurons may be translated into a tonic extracellular DA level, whereas their bursting activity can generate discrete extracellular DA transients.
Data collection and analysis strategies for phMRI
2014, Neuropharmacology
Although functional MRI traditionally has been applied mainly to study changes in task-induced brain function, evolving acquisition methodologies and improved knowledge of signal mechanisms have increased the utility of this method for studying responses to pharmacological stimuli, a technique often dubbed “phMRI”. The proliferation of higher magnetic field strengths and the use of exogenous contrast agent have boosted detection power, a critical factor for successful phMRI due to the restricted ability to average multiple stimuli within subjects. Receptor-based models of neurovascular coupling, including explicit pharmacological models incorporating receptor densities and affinities and data-driven models that incorporate weak biophysical constraints, have demonstrated compelling descriptions of phMRI signal induced by dopaminergic stimuli. This report describes phMRI acquisition and analysis methodologies, with an emphasis on data-driven analyses. As an example application, statistically efficient data-driven regressors were used to describe the biphasic response to the mu-opioid agonist remifentanil, and antagonism using dopaminergic and GABAergic ligands revealed modulation of the mesolimbic pathway. Results illustrate the power of phMRI as well as our incomplete understanding of mechanisms underlying the signal. Future directions are discussed for phMRI acquisitions in human studies, for evolving analysis methodologies, and for interpretative studies using the new generation of simultaneous PET/MRI scanners.
This article is part of the Special Issue Section entitled ‘Neuroimaging in Neuropharmacology’.
Histamine H<inf>3</inf> receptor activation prevents dopamine D<inf>1</inf> receptor-mediated inhibition of dopamine release in the rat striatum: A microdialysis study
2013, Neuroscience Letters
Citation Excerpt :
To confirm the effects of D1R activation on striatal DA release, 2 groups of rats (n = 3 per group) received an intra-striatal application of the D1R agonist SKF-38393 (0.5 or 1 μM). The concentrations of SKF-38393 were based on previous studies [16,29,42]. The role of D1Rs and H3Rs in striatal DA release was studied in 18 rats, which were separated into 3 groups: (a) intrastriatal application of the D1R agonist SKF-38393 (0.5 μM, n = 6); (b) co-administration of SKF-38393 and the H3R agonist immepip (10 μM, n = 6); and (c) co-administration of SKF-38393, immepip and the H3R antagonist thioperamide (10 μM).
Histamine H₃ receptors (H₃Rs) co-localize with dopamine (DA) D₁ receptors (D₁Rs) on striatal medium spiny neurons and functionally antagonize D₁R-mediated responses. The intra-striatal administration of D₁R agonists reduces DA release whereas D₁R antagonists have the opposite effect. In this work, a microdialysis method was used to study the effect of co-activating D₁ and H₃ receptors on the release of DA from the rat dorsal striatum. Infusion of the D₁R agonist SKF-38393 (0.5 and 1 μM) significantly reduced DA release (26–58%), and this effect was prevented by co-administration of the H₃R agonist immepip (10 μM). In turn, the effect of immepip was blocked by the H₃R antagonist thioperamide (10 μM). Our results indicate that co-stimulation of post-synaptic D₁ and H₃ receptors may indirectly regulate basal DA release in the rat striatum and provide in vivo evidence for a functional interaction between D₁ and H₃ receptors in the basal ganglia.

View all citing articles on Scopus

View full text

Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis

Abstract

European J. Pharmacol.

European J. Pharmacol.

Neuroscience

Brain Res.

European J. Pharmacol.

European J. Pharmacol.

European J. Pharmacol.

Brain Res.

Brain Res.

European J. Pharmacol.

European J. Pharmacol.

Life Sci.

European J. Pharmacol.

Dopamine's autoreceptors: Pharmacological characterization by microiontophoretic single cell recording studies

Naunyn-Schmiedeb. Arch. Pharmacol.

Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs

J. Pharmacol.

Selective stimulation of dopamine and noradrenaline autoreceptors by BHT 933, respectively

Naunyn-Schmiedeb. Arch. Pharmacol.

Regional cerebral glucose phosphorylation and blood flow after insertion of a microdialysis fiber through the dorsal hippocampus in the rat

J. Neurochem.

Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity

J. Pharmacol. Exp. Ther.